To identify possible drugs to combine with nelarabine in this context, the authors also conducted a whole genome CRISPR screen in an AML cell model with acquired resistance to nelarabine, using nelarabine treatment as phenotypic selection in the screen, and identified DUSP6 (dual-specificity phosphatase 6) as one hit. The gene discussed is DUSP6; the disease is acute myeloid leukemia.